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ORIGINAL ARTICLE
Hepatocyte MyD88 affects bile acids, gut microbiota
and metabolome contributing to regulate glucose
and lipid metabolism
Thibaut Duparc,1,2 Hubert Plovier,1,2 Vannina G Marrachelli,3 Matthias Van Hul,1,2
Ahmed Essaghir,4 Marcus Ståhlman,5,6 Sébastien Matamoros,1,2 Lucie Geurts,1,2
Mercedes M Pardo-Tendero,3 Céline Druart,1,2 Nathalie M Delzenne,2
Jean-Baptiste Demoulin,4 Schalk W van der Merwe,7,8 Jos van Pelt,7
Fredrik Bäckhed,5,6,9 Daniel Monleon,3 Amandine Everard,1,2 Patrice D Cani1,2
ABSTRACT
Objective To examine the role of hepatocyte myeloid
differentiation primary-response gene 88 (MyD88) on
glucose and lipid metabolism.
Design To study the impact of the innate immune
system at the level of the hepatocyte and metabolism,
we generated mice harbouring hepatocyte-speciﬁc
deletion of MyD88. We investigated the impact of the
deletion on metabolism by feeding mice with a normal
control diet or a high-fat diet for 8 weeks. We evaluated
body weight, fat mass gain (using time-domain nuclear
magnetic resonance), glucose metabolism and energy
homeostasis (using metabolic chambers). We performed
microarrays and quantitative PCRs in the liver. In
addition, we investigated the gut microbiota
composition, bile acid proﬁle and both liver and plasma
metabolome. We analysed the expression pattern of
genes in the liver of obese humans developing non-
alcoholic steatohepatitis (NASH).
Results Hepatocyte-speciﬁc deletion of MyD88
predisposes to glucose intolerance, inﬂammation and
hepatic insulin resistance independently of body weight
and adiposity. These phenotypic differences were
partially attributed to differences in gene expression,
transcriptional factor activity (ie, peroxisome proliferator
activator receptor-α, farnesoid X receptor (FXR), liver X
receptors and STAT3) and bile acid proﬁles involved in
glucose, lipid metabolism and inﬂammation. In addition
to these alterations, the genetic deletion of MyD88 in
hepatocytes changes the gut microbiota composition and
their metabolomes, resembling those observed during
diet-induced obesity. Finally, obese humans with NASH
displayed a decreased expression of different
cytochromes P450 involved in bioactive lipid synthesis.
Conclusions Our study identiﬁes a new link between
innate immunity and hepatic synthesis of bile acids and
bioactive lipids. This dialogue appears to be involved in
the susceptibility to alterations associated with obesity
such as type 2 diabetes and NASH, both in mice and
humans.
INTRODUCTION
The innate immune system and metabolic pathways
are functionally intertwined,1 2 making them
attractive targets for treating obesity and related
disorders (ie, diabetes, non-alcoholic fatty liver dis-
eases (NAFL) and cardiometabolic diseases).
Growing evidence suggests that the innate immune
system acts as a metabolic sensor against nutritional
stresses. Multiple innate immune receptors such as
toll-like receptors (TLRs), nucleotide oligomerisa-
tion domain (NOD) and NOD-like receptor family
members have been implicated in the recognition
Signiﬁcance of this study
What is already known on this subject?
▸ Toll-like receptors and myeloid differentiation
primary-response gene 88 (MyD88) have been
linked with several metabolic pathways.
▸ Conﬂicting results exist regarding the role of
innate immunity and more precisely MyD88 on
host metabolism.
▸ The liver is a key organ targeted by the
microbiota and involved in the control of
glucose and lipid metabolism.
What are the new ﬁndings?
▸ The hepatocyte deletion of MyD88 predisposes
to glucose intolerance, inﬂammation and
hepatic insulin resistance independently of
body weight and adiposity.
▸ Hepatocyte Myd88 controls the synthesis of
bioactive lipids involved in glucose, lipid
metabolism and inﬂammation.
▸ Hepatocyte Myd88 regulates the transcriptional
activity of several genes involved in bile acid
metabolism.
▸ The hepatocyte deletion of MyD88 under
normal diet induces changes of speciﬁc gut
microbes, genes expression, plasma and liver
metabolome that resemble those observed in
diet-induced obese and diabetic mice.
▸ Similar to what is seen in hepatocyte Myd88
deleted mice, human obese subjects developing
non-alcoholic steatohepatitis (NASH) are
characterised by a decreased expression of
different cytochromes P450 involved in
bioactive lipids synthesis.
To cite: Duparc T, Plovier H, 
Marrachelli VG, et al. Gut 
2017;66:620–632.
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http://dx.doi.org/10.1136/
gutjnl-2015-310904)
For numbered affiliations see 
end of article.
Correspondence to
Professor Patrice D Cani, 
Université catholique de 
Louvain, WELBIO, LDRI, 
Metabolism and Nutrition 
research group, Av. E. Mounier, 
73 box B1.73.11, Brussels 
B-1200, Belgium;  
patrice.cani@uclouvain.be
Received 14 October 2015
Revised 1 March 2016
Accepted 3 March 2016
Published Online First 
5 May 2016
Gut microbiota
620 Duparc T, et al. Gut 2017;66:620–632. doi:10.1136/gutjnl-2015-310904
group.bmj.com on January 15, 2018 - Published by http://gut.bmj.com/Downloaded from 
of metabolic stresses and in the onset of inﬂammatory
responses, thereby contributing to the development of metabolic
disorders.2 3 We and others have shown that low-grade inﬂam-
mation and insulin resistance may be linked to gut microbiota
and are dampened in the absence of speciﬁc TLRs.4–6 However,
numerous conﬂicting results exist.7–10 For instance, data suggest
that TLR-4 receptor signalling is not directly required for fatty
acid-induced hepatic insulin resistance,10 while others show that
liver-speciﬁc deletion of TLR-4 protects against diet-induced
hepatic insulin resistance.11 12
Myeloid differentiation primary-response gene 88 (MyD88)
is the key signalling adaptor for most TLRs (with the exception
of TLR-3), interleukin-1 receptor (IL-1R) and IL-18 receptor.
MyD88 has been shown to play a role in obesity and diabetes.
Non-obese diabetic mutant mice, which are prone to the devel-
opment of type 1 diabetes mellitus, are protected from the
disease if MyD88 is ablated, and this protection may be trans-
ferred following gut microbiota transfer into germfree recipient
mice.7 Deleting MyD88 in the central nervous system or intes-
tinal epithelial cells protects against high-fat diet (HFD)-induced
weight gain and glucose intolerance.13 14 In another context,
the deletion of MyD88 has been shown to increase the risk of
developing type 2 diabetes and hepatic steatosis under HFD
feeding.15–17 Altogether, evidence strongly supports a role of
MyD88 signalling in hepatic disturbances associated with
obesity; however, the convergent molecular mechanisms and
target tissues remain to be clariﬁed.
To evaluate the speciﬁc role of hepatocyte MyD88 on metab-
olism, we generated a mouse model of hepatocyte-speciﬁc dele-
tion of Myd88 gene. We next investigated the impact of the
deletion under physiological (control diet (CT)) and patho-
logical (HFD-induced obesity) conditions.
MATERIALS AND METHODS
Mice
Generation of Albumin-Myd88 KO mice
Hepatocyte-speciﬁc Myd88 deleted mice (liver-speciﬁc knockout
mice (LKO)) were generated by crossing mice bearing the Cre
recombinase expressed under the control of the Albumin pro-
moter (Albumin-Cre) (C57BL/6 background, Jackson Laboratory,
Bar Harbor, Maine, USA) with mice harbouring a loxP-ﬂanked
Myd88 allele (C57BL/6 background, Jackson Laboratory).
LKO experiments
Cohorts of 8-week-old LKO mice and wild-type (WT) litter-
mates were housed in speciﬁc pathogen-free conditions in
groups of two mice/cage (ﬁlter-top cages) with free access to
food and autoclaved water. The WT and LKO mice were fed a
CT (10% fat, AIN93Mi, Research Diet, New Brunswick, New
Jersey, USA) (WT-CT or LKO-CT) or an HFD (60% fat,
D12492i, Research Diet) (WT-HFD or LKO-HFD). Treatment
continued for 8 weeks. This experiment was replicated inde-
pendently three times. The control mice were WT littermates
harbouring the Myd88 loxP-ﬂanked allele but not the Cre
recombinase. Body weight and food intake were recorded once
a week. Body composition was assessed once a week using 7.5
MHz time-domain nuclear magnetic resonance (LF50 Minispec,
Bruker, Rheinstetten, Germany).
Additional protocols and procedures are described in the
online supplementary method section.
Statistical analyses
The data are expressed as the mean±SEM. Differences between
the groups were assessed using one-way analysis of variance
(ANOVA), followed by Newman–Keuls post hoc tests after nor-
malisation by log transformation. A two-way ANOVA analysis
with a Bonferroni post test on repeated measurements was per-
formed for the evolution of body weight, fat mass and gly-
caemia during the oral glucose tolerance test. The data were
analysed using GraphPad Prism V.5.00 for Windows (GraphPad
Software, San Diego, California, USA). Data with different
superscript letters or symbols are signiﬁcantly different at
p<0.05 according to the post hoc ANOVA statistical analysis.
Accession numbers
The GEO accession number for the microarray data reported in
this paper is GSE73489. The GEO accession number of the
human microarray data set is GSE59045.
RESULTS
Hepatocyte Myd88 deletion does not affect body weight
and fat mass gain
To assess the role of hepatocyte MyD88 on metabolism, we
generated mice with a conditional hepatocyte-speciﬁc deletion
of Myd88 gene (LKO mice). We validated the deletion of
Myd88 gene in the hepatocyte of LKO mice by quantifying
both mRNA (decreased by 50%) and protein levels in the
liver of WT and LKO mice (see online supplementary ﬁgure
S1A, B).
We next assessed whether hepatocyte Myd88 deletion altered
host metabolism and phenotype upon either a CT (WT-CT and
LKO-CT groups) or an HFD (WT-HFD and LKO-HFD
groups). We found that hepatocyte Myd88 deletion did not
affect body weight throughout the 8 weeks of treatment com-
pared with WT mice. Both WT and LKO mice gained similar
weight during chronic treatment with HFD (ﬁgure 1A, C).
Body composition analysis using NMR showed that LKO mice
gained similar fat mass throughout the experiment as WT mice
under either CT or HFD challenge (ﬁgure 1B, D). Liver weight
and fat pads were not affected by the hepatic Myd88 deletion
(ﬁgure 1E–H). Mean food intake was similar between groups
(ﬁgure 1I).
By using metabolic chambers, we analysed the total physical
activity level and the respiratory exchange ratio. We did not ﬁnd
any differences between groups when comparing total physical
activity (ﬁgure 1J). However, LKO mice under a CTwere char-
acterised by a lower respiratory exchange ratio similar to mice
fed an HFD, showing the use of fatty acids as preferential
energy substrate as found during HFD feeding, thereby suggest-
ing a reduced oxidation of glucose substrates (ﬁgure 1K).
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ We identiﬁed novel mechanisms associating the hepatic
innate immunity cell signalling through MyD88 and its
implication in the onset of diabetes.
▸ We propose a speciﬁc pattern of expression of different
cytochromes and bioactive lipids in liver tissue of obese
patients that may serve as a marker of susceptibility to
develop NASH.
▸ Our study takes a step towards the identiﬁcation of bioactive
lipids produced by the liver and metabolites linking
immunity and metabolism.
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Altered glucose metabolism in LKO mice
We next assessed whole-body glucose metabolism and found
that hepatocyte Myd88 deletion did not affect oral glucose tol-
erance under CT, whereas LKO-HFD mice exhibited impaired
glucose tolerance compared with WT-HFD mice (ﬁgure 2A,
B). As expected, HFD feeding signiﬁcantly increased plasma
insulin levels area under the curves after the oral glucose load
(ﬁgure 2C). Although the glucose proﬁle was not affected in
LKO-CT, these mice produced signiﬁcantly more insulin in
response to oral glucose administration to maintain a normal
glycaemia, suggesting an insulin resistance state (ﬁgure 2C).
Under HFD treatment, LKO-HFD mice increased insulin secre-
tion by about 60% compared with WT-HFD mice. These
results were supported by an impaired insulin resistance index,
with LKO-HFD mice displaying a 70% increase compared
with WT-HFD mice (ﬁgure 2D). We next assessed insulin tol-
erance by using an insulin tolerance test. This parameter was
moderately but non-signiﬁcantly affected in LKO-HFD (ﬁgure
2E). Insulin resistance index is considered as a surrogate of
hepatic insulin resistance.18 In accordance with this assump-
tion, we found a lower hepatic glycogen content (whose
synthesis and degradation is controlled by insulin19) in
LKO-CT, WT-HFD and LKO-HFD mice compared with
WT-CT mice (ﬁgure 2F).
To explore whether LKO mice develop insulin resistance in
the liver, we analysed insulin-induced phosphorylation of Akt
(p-Akt). We found that phosphorylation of Akt after insulin
stimulation was reduced in the liver of LKO-CT mice; this effect
was signiﬁcantly more pronounced in LKO-HFD mice (ﬁgure
2G, H). Visceral fat inﬂammation is associated with a lower
glucose tolerance and an increased hepatic insulin resistance.20
Here, we found that LKO mice displayed a signiﬁcantly
increased (about 65%) mRNA expression of the cluster of differ-
entiation 11c (CD11c) subpopulation of macrophages in visceral
adipose tissue, which is the primary population of adipose tissue
macrophages in obesity and insulin resistance (ﬁgure 2I).21 22
This parameter was increased by 2.3-fold in WT-HFD and even
more so 3.5-fold in LKO-HFD mice (ﬁgure 2I).
Figure 1 Hepatocyte myeloid differentiation primary-response gene 88 (Myd88) deletion does not affect body weight and fat mass development.
(A) Body weight evolution (g). (B) Fat mass evolution (g) measured by time-domain nuclear magnetic resonance (TD-NMR). (C) Total body weight
gain (g). (D) Total fat mass gain (g) measured by TD-NMR. (E) Liver weight (mg). (F) Subcutaneous adipose tissue (SAT) weight (mg). (G) Epididymal
adipose tissue (EAT) weight (mg). (H) Visceral adipose tissue (VAT) weight. (I) Food intake (g/day/mouse). ( J) Total physical activity measured in
metabolic chambers (total beam breaks counts). (K) Respiratory exchange ratio (VCO2/VO2). These data (A–H) correspond to the results of at least
three independent experiments (n=25–36), (I) (n=10/groups), ( J and K) (n=4–6 per groups). Data are presented as mean±SEM. *Signiﬁcant
differences (p<0.05) between high-fat diet (HFD)-treated groups versus control diet (CT)-treated mice. Data with different superscript letters or
symbols are signiﬁcantly different (p<0.05) according to post hoc one-way analysis of variance. LKO, liver-speciﬁc knockout mice; WT, wild type.
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Hepatic function and lipid content in LKO mice
We next assessed whether hepatic Myd88 deletion had an inﬂu-
ence on transaminase levels reﬂective of liver inﬂammation. We
found that plasma alanine aminotransferase (ALT) levels were
mostly increased in HFD-treated mice, whereas aspartate ami-
notransferase (AST) levels were increased by about 30% in
LKO-CT mice and HFD-fed mice but did not reach signiﬁcance
(ﬁgure 3A, B). We found that liver lipid content is signiﬁcantly
changed upon HFD feeding with a 50% increase in WT-HFD
and 65% increase in LKO-HFD hepatic triglycerides content
(ﬁgure 3C). These results were further conﬁrmed by using histo-
logical analyses and steatosis score (ﬁgure 3D, E). Inﬂammatory
score was signiﬁcantly increased following HFD feeding but not
affected by the Myd88 deletion (ﬁgure 3F). Fibrosis score was
similar between groups (ﬁgure 3G).
Gene expression proﬁle in the liver of LKO mice
To understand the mechanisms involved in the development of
hepatic steatosis and insulin resistance, we performed a global
gene expression analysis by using microarrays. These microar-
rays revealed the increased expression of a large number of
genes involved in acute phase response and inﬂammatory path-
ways, lipid metabolism and the decreased expression of numer-
ous genes related to cytochrome P450-mediated oxidation and
reduction (ﬁgure 4A). The signiﬁcance of these pathways was
obtained by analysing gene ontology using the bioinformatics
tools DAVID and TFactS23–25 (Document S1 DAVID and online
supplementary ﬁgure S2). Figure 4A represents genes that were
downregulated or upregulated 1.5-fold in LKO-CT, LKO-HFD
and WT-HFD mice versus WT-CT mice. Heat maps of selected
genes similarly affected between different conditions were used
to compare the expression of the same genes in the three condi-
tions matched with the WT-CT group. We found that numerous
important pathways were modiﬁed following hepatic Myd88
deletion under both CTand HFD treatment (ﬁgure 4A). We dis-
covered that 425 genes were signiﬁcantly affected in LKO-CT
mice, whereas HFD feeding induces the modiﬁcation of 890
genes and 1168 genes signiﬁcantly modiﬁed in LKO-HFD com-
pared with WT-CT mice (ﬁgure 4A). Among these changes, 167
genes were signiﬁcantly and similarly affected in the three con-
ditions LKO-CT, WT-HFD and LKO-HFD (see ﬁgure 4A and
online supplementary table S1). Several genes involved in
inﬂammation and acute phase response such as Saa1, Saa2,
Saa3, Orm1 and Orm2 were signiﬁcantly and strongly induced
in LKO-CT compared with WT-CT mice, and even at a higher
level than in the HFD-fed mice (ﬁgure 4B–F). Lcn2, a gene
involved in innate immunity, was signiﬁcantly increased in hep-
atocyte MyD88 deleted mice under both CT and HFD condi-
tions (ﬁgure 4G). Genes involved in immunity and defence such
as Cd43, C4A, Cd8b1 and Cxcl1 were signiﬁcantly increased in
LKO-CT, WT-HFD and LKO-HFD mice compared with WT-CT
(ﬁgure 4H–K).
Surprisingly, numerous genes involved in oxidation and
reduction (ie, cytochrome P450) pathways were decreased in
Figure 2 Hepatocyte myeloid
differentiation primary-response gene
88 (Myd88) deletion alters glucose
tolerance, whole-body lipid
metabolism and promotes insulin
resistance. (A) Plasma glucose (mg/dL)
proﬁle after 2 g/kg glucose oral
challenge in freely moving mice and
(B) the mean area under the curve
(AUC) measured between 0 and
120 min after glucose loading. (C) AUC
plasma insulin of measured between –
30 and 15 min after glucose loading.
(D) Insulin resistance index determined
by multiplying the AUC of blood
glucose by the AUC of insulin. (E)
Plasma glucose proﬁle after
intraperitoneal insulin injection
(0.75 U/kg) in freely moving mice
(n=9–10). (F) Liver glycogen (mg of
glucose from glycogen/mg of liver)
content measured in fasted mice. (G)
Total and phosphorylated Akt levels in
the liver of mice after intraportal
insulin injection and (H) % of
phosphorylation of Akt protein (n=3).
(I) Visceral adipose tissue CD11c
mRNA expression. These data (A–D, F
and I) correspond to the results of at
least three independent experiments
(n=25–36). Data are presented as
mean±SEM. Data with different
superscript letters or symbols are
signiﬁcantly different (p<0.05)
according to post hoc one-way analysis
of variance. CT, control diet; HFD,
high-fat diet; LKO, liver-speciﬁc
knockout mice; WT, wild type.
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LKO-CT mice and the HFD-treated groups (ﬁgure 4A). Among
these genes, decreased both by hepatocyte MyD88 deletion and
HFD, we found several cytochromes involved in long-chain
fatty acid metabolism and, more speciﬁcally, in the synthesis of
epoxyeicosatrienoic acids (EETs), hydroxyepoxyeicosatrienoic
(HETEs) and dihydroxyepoxyeicosatrienoic (DHETs) acids
family.26 These lipids have been shown to regulate glucose, lipid
and inﬂammatory processes. For instance, EETs, HETEs and
DHETs reduce liver lipids and inﬂammation,27 they act as
insulin sensitisers,29 anti-inﬂammatory molecules30 and reduce
metabolic syndrome markers.31 Strikingly, EETs are also
reported as peroxisome proliferator activator receptor-α
(PPAR-α) agonists.32 33 Liver transcription factor PPAR-α activa-
tion has been shown to modulate numerous pathways such as
lipid metabolism (eg, fatty acid synthesis, fatty acid oxidation,
bile acid synthesis). By using TFactS analyses, we found that
LKO mice exhibited a strong and signiﬁcant inhibition of
PPAR-α, NR1H3 and NR1H2 (liver X receptors (LXR)α and
LXRβ, respectively) (p<0.0005), whereas STAT3 was signiﬁ-
cantly activated (p=0.01) (see online supplementary ﬁgure S2).
The inhibition of PPAR-α is in line with the phenotype
observed, which is an increased inﬂammation, hepatic steatosis
and altered insulin sensitivity. Interestingly, the downregulation
of ﬁbroblast growth factor 21 (Fgf21) has been associated with
the activation of STAT3, which induces higher hepatic glucose
production and glycogenolysis.34 Here, we found that Fgf21
expression was decreased by 50% in LKO mice and 80% in
both WT-HFD and LKO-HFD mice, thereby leading to STAT3
activation and lower glycogen content in these three groups
(ﬁgure 5A). The downregulation of LXR may also contribute to
change in immunity, bile acids, glucose and lipid metabolism.35
Changes in bile acid metabolism and proﬁle in LKO mice
Among the cytochromes affected by the hepatocyte Myd88 dele-
tion, we found that mRNA levels of Cyp7a1, Cyp8b1 and
Cyp7b1, key cytochromes involved in bile acids synthesis, were
increased in LKO-CT, WT-HFD and LKO-HFD mice (ﬁgure
5B–D). The expression of Cyp27a1, which is mostly involved in
the alternative pathway of bile acid synthesis, was not affected
(ﬁgure 5E). Fgf15 is produced in the ileum and signals through
Fgfr4 in hepatocytes to inhibit expression of the major cyto-
chromes involved in bile acid synthesis.36 Strikingly, we found
that the expression of Fgf15 in the ileum was doubled in
LKO-CT mice compared with WT-CT and increased by about
10-fold to 12-fold under HFD feeding (ﬁgure 5G), whereas
WT-HFD and LKO-HFD mice exhibited a signiﬁcantly lower
mRNA expression of Fgfr4 (ﬁgure 5H), thereby suggesting the
existence of an altered negative feedback loop of bile acid syn-
thesis from the gut to the hepatocytes.
Several markers of bile acid metabolism pointed towards a
putative modulation of the bile acid proﬁle. Therefore, we quan-
tiﬁed more than 20 different bile acids in the portal vein and in
the caecum (see ﬁgure 5F, I and online supplementary ﬁgure
S3). We found that HFD feeding affected both primary and sec-
ondary bile acids such as CA, TbMCA, TCA, THDCA, TCDCA
and TDCA, whereas others were unaffected (see ﬁgure 5F, I and
online supplementary ﬁgure S3). Interestingly, hepatic Myd88
deletion mimicked HFD feeding with the major bile acid CA
signiﬁcantly decreased in the plasma and the caecum of both
LKO-CT and WT-HFD mice compared with WT-CT mice
(ﬁgure 5F, I). Conversely, in the plasma, TbMCA levels were sig-
niﬁcantly increased in LKO-CT reaching the same levels as those
observed in HFD-fed mice (ﬁgure 5F). We next measured
markers of bile acid metabolism in the liver and in the intestine.
More precisely, we quantiﬁed factors involved in bile acid conju-
gation (Bal, Bat, Hnf4a1) (ﬁgure 6A), in the export of bile acids
from the liver (Abcb11, Abcb4, Ostb) (ﬁgure 6B) and in the
reabsorption of bile acids (Ntcp, Otap1b2) (ﬁgure 6C). In add-
ition, we measured markers of bile acid reabsorption in the
ileum (Osta, Ostb, Ibabp, Asbt) (ﬁgure 6D). Most of these
markers were not affected by the absence of MyD88 and tend
to be affected by the dietary treatment (ie, Bal, Osta and Ibabp).
Importantly, CA and TbMCA are known to regulate FXR
activity.37 38 Thus, these results strongly suggest that the
Figure 3 Hepatocyte myeloid
differentiation primary-response gene
88 (Myd88) deletion and hepatic
parameters. (A) Plasma ALT activity.
(B) Plasma AST activity. (C) Hepatic
triglycerides (nmol/mg of protein)
(n=20–27). (D) Representative
histological liver oil red O staining,
scale bar=100 mm. (E) Hepatic
steatosis score (arbitrary units). (F)
Inﬂammation score (arbitrary units).
(G) Fibrosis score (% of area). Data are
presented as mean±SEM. These data
(A–C) correspond to the results of at
least three independent experiments
(n=23–38), scores obtained in (E) and
(F) have been obtained following the
analysis of at least ﬁve ﬁelds per
animal (n=8–11 per groups) and by
three independent blinded
investigators. Data with different
superscript letters or symbols are
signiﬁcantly different (p<0.05)
according to post hoc one-way analysis
of variance. CT, control diet; HFD,
high-fat diet; LKO, liver-speciﬁc
knockout mice; WT, wild type.
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decrease in the main agonist CA and the increase in the antag-
onist TbMCA in LKO mice reduce the activity of FXR (ﬁgure
5J), thereby contributing to the observed changes on both
glucose and lipid metabolism. In accordance with this hypoth-
esis, we found that expression ﬂavin mono oxygenase 3, a gene
regulated by FXR,39 was the most reduced in LKO-CT,
WT-HFD and LKO-HFD mice (ﬁgure 4A), further supporting a
link between the gene proﬁle, FXR and bile acid metabolism.
Deletion of hepatocyte Myd88 affects speciﬁc gut bacteria
Bile acids, HFD feeding and FXR have been associated with
changes in gut barrier functions, insulin resistance and gut
microbes.40–43 In the present study, we investigated different
markers of gut barrier function in the jejunum and in the ileum.
We found that the expression of the antimicrobial peptide
RegIIIγ (regenerating islet-derived 3 gamma, encoded by Reg3g)
was strongly decreased in WT-HFD and even more in
LKO-HFD in the jejunum and to a lower extent in the ileum
(see online supplementary ﬁgure S4A, C). The other markers of
tight-junction proteins (claudin 1 and 3, zonula occludens 1 and
occludin) were weakly affected (see online supplementary ﬁgure
S4B, D).
Bile acids are metabolised by different microbes. Because we
found a clear change in the bile acid proﬁle upon both genetic
deletion of Myd88 and HFD feeding, we investigated whether
this observation might be associated with changes in gut micro-
biota composition. Consistent with previous studies,5 14 44 45
HFD feeding signiﬁcantly changed gut microbiota composition
compared with WT-CT mice (see ﬁgure 7A, B and online sup-
plementary table S2). The deletion of Myd88 did not signiﬁ-
cantly affect the major phyla (ﬁgure 7B) nor the number of
operational taxonomic units (OTUs) (see online supplementary
ﬁgure S5A). A total of 43 881 OTUs were identiﬁed by the
QIIME pipeline, represented by at least one sequence in one
sample. Samples were then grouped by treatment, and the
median number of sequences in each group was calculated for
each OTU. In total, 1852 OTUs have a median abundance
superior to 0 in at least one treatment group, with 191 OTUs
Figure 4 Hepatocyte myeloid
differentiation primary-response gene
88 (Myd88) deletion changes gene
proﬁle and transcriptional activity in
the liver. (A) Heat map from microarray
analysis and transcriptional factors
representing selected genes involved in
inﬂammation, innate immunity, host
defence, oxidation and reduction
pathways. This list contains the list of
genes signiﬁcantly downregulated or
upregulated 1.5-fold in liver-speciﬁc
knockout (LKO)-control diet (CT), wild
type (WT)-high-fat diet (HFD), LKO-HFD
mice versus WT-CT mice (p<0.05).
Expression of markers involved in
acute phase response (B) Saa1, (C)
Saa2, (D) Saa3, (E) Orm1 and (F)
Orm2; genes involved in innate
immunity and defence (G) Lcn2, (H)
C4A, (I) Cd8b1, ( J) Cd43, (K) Cxcl1
measured by microarrays.
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accounting for 90% of the sequences. In total, 1113 OTUs have
a median abundance superior to 0 in either the LKO-CT or
WT-CT groups, and 751 in both groups. Also, 172 OTUs had a
cumulated median of abundance in both LKO-CT and WT-CT
groups superior to 10, representing 89.26% of the total
sequences. These OTUs are represented in online supplementary
ﬁgure S5B as the core microbiome of the control treatment
group. The OTUs are divided into ﬁve phyla: Firmicutes,
Bacteroides, Proteobacteria, Tenericutes and Deferribacteres.
The core microbiome of the mice in the experiment is actually
represented by a relatively limited number of OTUs: <10% of
the OTUs with a median abundance superior to 0 account for
Figure 5 Hepatocyte myeloid differentiation primary-response gene 88 (Myd88) deletion increases mRNA expression of genes involved in bile acid
synthesis and signalling and affects plasma bile acid proﬁle. (A) Fgf21 expression issued from the microarray analysis, (B) Cyp7a1 mRNA, (C) Cyp8b1
mRNA, (D) Cyp7b1 mRNA and (E) Cyp27a1 mRNA levels measured by qPCR in the liver of wild type (WT)-control diet (CT), liver-speciﬁc knockout
(LKO)-CT, WT-high-fat diet (HFD) and LKO-HFD mice. These data correspond to the results of at least two independent experiments (n=12–20). Data
are presented as mean±SEM. Data with different superscript letters are signiﬁcantly different (p<0.05) according to post hoc one-way analysis of
variance (ANOVA). (F) Plasma bile acids content (% of total bile acids), TCA, TUDCA, THDCA, TCDCA, TDCA, CA, UDCA, HDCA, CDCA, DCA, TbMCA,
TaMCA, ToMCA, oMCA, aMCA, bMCA. Data are presented as mean±SEM (n=9–10). (G) Fgf15 mRNA in the ileum (n=12) and (H) Fgfr4 mRNA
(n=10–20) in the liver of WT-CT, LKO-CT, WT-HFD and LKO-HFD. (I) Caecum bile acids content (% of total bile acids). Data are presented as mean
±SEM (n=9–10). ( J) Graphical summary: impact of a decreased abundance of FXR agonist and an increased abundance of FXR antagonist, leading
to a decreased FXR activity and altered glucose, lipid metabolism. Data with different superscript letters are signiﬁcantly different (p<0.05)
according to post hoc one-way ANOVA. CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; HDCA, hyodeoxycholic acid; LCA,
lithocholic acid; MCA, muricholic acid; T, taurine; UDCA, ursodeoxycholic acid. a, alpha; b, beta; o, omega conjugated species.
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almost 90% of the total number of sequences. The phylotype
richness estimated according to the bias-corrected Chao1 were
similar between groups (see online supplementary ﬁgure S5BC),
whereas Shannon diversity index was increased in treated
groups (see online supplementary ﬁgure S5D).
At a lower taxonomic level, we found that the abundance of
Sutterella and Allobaculum was strongly and signiﬁcantly
decreased in LKO-CT and, to a similar extent, as observed
during HFD feeding (see online supplementary table S3 and
ﬁgure 7C, D). We also established that Ruminococcus and
Oscillospira were signiﬁcantly augmented in LKO-CT (about
60–100% increase) compared with WT-CT mice, whereas HFD
feeding further increased these two genera (ﬁgure 7E–F). Other
genera such as Dorea, Anaeroplasma, Odoribacter and
Coprococcus were mainly affected by the HFD treatment (ﬁgure
7G–J). Among the 16 genera that were signiﬁcantly modiﬁed
under HFD, 4 of them were also similarly affected in LKO-CT
mice (ie, Sutterella, Allobaculum, Ruminococcus and
Oscillospira). Therefore, these observations are in line with the
different metabolic markers and bile acid proﬁle showing that
LKO-CT mice exhibited a phenotype, which is close to
HFD-fed mice.
Deletion of hepatocyte Myd88 affects serum and liver
metabolome
In addition to the impact of gut microbes and bile acids on
metabolism, evidence suggests that numerous microbial metabo-
lites may contribute to host metabolism.46 47 1H NMR spec-
troscopy was carried out on liver and portal vein blood.
Metabolite assignments were based on previously published
data.48 49
A total of 45 metabolites in liver and 33 metabolites in blood
serum that originate from protein, amino acids, lipids,
carbohydrate and microbial metabolism were identiﬁed (see
online supplementary table S4, S5). HFD-fed mice exhibited
higher levels of fatty acids both in liver and in serum, lower
levels of albumin and higher levels of isoleucine in serum and
lower levels of glycogen and creatine phosphate in liver. The
numbers of N-acetyl groups of protein glycans (NAC2) in liver
were also increased under HFD treatment. Interestingly, the
deletion of Myd88 produced more metabolomic differences in
liver than in serum and under CT than under HFD. The liver of
LKO animals contained lower levels of acetoacetate but higher
levels of glutamate and arginine. LKO animals under CT showed
unique liver metabolomic features that are not present in
LKO-HFD animals, including changes in cholesterol, total
visible fatty acids, alanine, citrate, creatinine, choline, trimethy-
lamine N-oxide (TMAO), taurine, proline, glycine, total gluta-
thione and tyrosine. Similarly, these animals exhibited marked
lower levels of branched chain amino acids (isoleucine, leucine
and valine) and methylamines.
We performed chemometric analysis on the data for better
understanding of the metabolic similarities between groups. As
expected, the major modulator of host metabolism is the type of
diet (ﬁgure 8A, B). Similarly to what we observed in the individ-
ual metabolic levels, the genetic deletion has a minor impact in
serum metabolome and a moderate impact in liver metabolome.
As found for the gut microbiota composition, the genetic dele-
tion causes the liver metabolomes of CT diet to resemble those
of HFD-fed mice. To further explore the metabolomic relation-
ships between genetic deletion and diet, we built separated
PLS-DA models for the discrimination of LKO versus WTunder
CTor HFD treatment.
PLS-DA score plots show a stronger separation between LKO
and WT in the liver under both CT and HFD treatment than in
the serum (scores plots in online supplementary ﬁgure S6). We
Figure 6 Markers of bile acids metabolism in the liver and in the ileum. (A) Bile acids conjugation (Bal, Bat and Hnf4a1 mRNA). (B) Bile acids
export (Abcb11, Abcb4, Ostb) mRNA. (C) Bile acids reabsorption (Ntcp and Otap1b2) mRNA in the liver of wild type (WT)-control diet (CT),
liver-speciﬁc knockout (LKO)-CT, WT-high-fat diet (HFD) and LKO-HFD mice. (D) Bile acids reabsorption (Osta, Ostb, Ibabp, Asbt) mRNA in the ileum
of WT-CT, LKO-CT, WT-HFD and LKO-HFD mice (n=10–12). Data are presented as mean±SEM. Data with different superscript letters are signiﬁcantly
different (p<0.05) according to post hoc one-way analysis of variance.
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also found that the number of discriminant metabolites was
higher in the liver than in the serum (VIP scores in online sup-
plementary ﬁgure S6). The quality of our models was validated
by evaluation with coefﬁcient of variation and permutation tests
for the models (see quality parameters in legend of online sup-
plementary ﬁgure S6). In accordance with metabolic parameters
and microarrays, several markers such as cholesterol, long-chain
fatty acids, branched chain amino acids (leucine, isoleucine and
valine), markers of oxidation and reduction contribute to dis-
crimination between groups (see ﬁgure 8C–L, online supple-
mentary ﬁgure S6 and tables S4, S5). The metabolites
discriminating genetic deletion in CT diet were different and
more numerous than those in HFD (VIP scores in online
supplementary ﬁgure S6). HFD groups overlapped with LKO
samples when projected onto the CT treatment model scores
plots (see online supplementary ﬁgure S6A, S6B). Conversely,
CT groups overlapped with WTwhen projected onto the HFD
liver model scores plot (see online supplementary ﬁgure S6E)
but overlapped with the LKO when projected onto the HFD
serum model (see online supplementary ﬁgure S6G).
Changes in molecular pathways between obese and
non-alcoholic steatohepatitis patients
To further investigate whether speciﬁc observations made in
rodents were reliable in humans, we compared the expression
pattern of genes in the liver of obese humans undergoing baria-
tric surgery, which were comparable with regard to body mass
index and age but stratiﬁed based on the severity of liver disease
into NAFLD and non-alcoholic steatohepatitis (NASH).22 We
found consistent results compared with what was observed in
our rodent model. To understand the differences in molecular
processes in the liver, we introduced the differentially expressed
genes, identiﬁed from the microarray into the STRING
program.50 This program weights and integrates information
Figure 7 Hepatocyte myeloid differentiation primary-response gene 88 (Myd88) deletion changes gut microbiota composition. (A) PCoA based on
the unweighted UniFrac analysis on operational taxonomic units (OTUs) (n=12). Each symbol representing a single sample is coloured according to
the group. (B) Composition of abundant bacterial phyla identiﬁed in the gut microbiota (n=12). (C–J) Relative abundances (percentage of 16S rRNA
sequences) of the various bacterial genera in each sample among each group of mice. Data are presented as mean±SEM (n=9–10). Data with
different superscript letters are signiﬁcantly different (p<0.05) according to post hoc one-way analysis of variance. See also online supplementary
tables S2 and S3. CT, control diet; HFD, high-fat diet; LKO, liver-speciﬁc knockout mice; WT, wild type.
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from numerous sources, including experimental repositories,
computational prediction methods and public text collections,
thus acting as a metadatabase that maps all interaction evidence
onto a common set of genomes and proteins. In addition to a
graphic representation of the predicted interactions, the
program generates a list of the most relevant gene-to-gene inter-
actions. The complexity of the interactions can be visualised
where a blue line represents a reported relationship between the
two genes and the thickness of the line represents the conﬁ-
dence (more literature results show a thicker line). The results
are shown in online supplementary ﬁgure S7. The 10 most sig-
niﬁcant Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways and 10 most signiﬁcant biological processes as com-
puted by this program are shown in online supplementary table
S7. Important to note is that most of the observations made in
the MyD88 model are also seen in patients. The most signiﬁcant
pathways and the biological processes are located in the right
and top sections of the ﬁgure.
DISCUSSION
In the present study, we demonstrate that hepatocyte Myd88
deletion induces profound changes in glucose and lipid metabol-
ism. Among the mechanisms, we found that hepatocyte Myd88
deletion modiﬁes transcriptomic proﬁle of genes involved in
both inﬂammation and metabolic pathways. These modiﬁcations
were associated with an altered bile acid proﬁle and pointed
towards modiﬁcations of several bioactive lipids and transcrip-
tional factors involved in both glucose and lipid metabolism (ie,
PPAR-α, FXR, LXR and STAT3). In addition to these altera-
tions, mice display an altered gut microbiota composition and
metabolomic proﬁle. We found that this phenotype already
occurred under normal chow diet, suggesting an HFD-like
metabolic phenotype, since only a few other parameters were
worsened under HFD. Strikingly, the absence of hepatic
MyD88 did not alter diet-induced body weight gain and fat
mass development. This surprising ﬁnding is not in accordance
with several other studies, suggesting that mice lacking MyD88
in the brain or in the gut are protected against both diet-induced
obesity and insulin resistance.11–14 Therefore, our data strongly
suggest that MyD88 differentially contributes to the regulation
of energy and glucose homeostasis depending on the targeted
organ. This also partially explains the quantity of conﬂicting
data existing when investigating whole-body Myd88 deletion
and its impact of obesity and related disorders.15–17
We showed that LKO mice had a normal glucose tolerance on
CT diet. However, in this dietary condition, LKO mice already
exhibited signiﬁcantly lower hepatic glycogen content and a
higher insulin secretion after oral glucose stimulation. They had
Figure 8 Hepatocyte myeloid differentiation primary-response gene 88 (Myd88) deletion changes the metabolomic proﬁle of the serum and the
liver. PCoA based on the nuclear magnetic resonance (NMR) metabolomic proﬁle of serum (A) and liver tissue (B). Each symbol represents a single
sample coloured according to the group. See also online supplementary tables S4 and S5. NMR integrals for metabolic regions most signiﬁcant
relative to the wild type (WT)-control diet (CT) average. (C) Cholesterol in serum. (D) Cholesterol in liver. (E) Arachidonic acid in liver. (F) Linoleic
acid in liver. (G) Isoleucine in serum. (H) Trimethylamines in serum. (I) Trimethylamine oxide (TMAO) in liver. ( J) Total glutathione in liver. (K)
N-Acetyl groups of protein glycans in liver. (L) L-Arginine in the liver. HFD, high-fat diet; LKO, liver-speciﬁc knockout mice.
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a trend to a lower insulin-induced phosphorylation of Akt, and
higher liver lipid content and a higher visceral adipose tissue
inﬂammation, suggesting that LKO mice develop an early
hepatic insulin resistance and have an altered metabolism. In
accordance with this hypothesis, we discovered that LKO mice
develop marked visceral adipose tissue inﬂammation, glucose
intolerance and insulin resistance during HFD feeding. To better
explain the phenotype observed in hepatic Myd88 deleted mice,
we performed a transcriptional analysis of the liver by microar-
rays. These revealed that several genes were signiﬁcantly differ-
ent between LKO-CT and WT-CT mice, and that these genes
were similarly upregulated or downregulated in HFD-CT and
HFD-LKO mice, corroborating the fact that lacking hepatocyte
Myd88 triggers an HFD-like phenotype in this set of mice.
Although these data have been obtained by using a microarray
approach using one set of mice, we have conﬁrmed most of the
variations of gene expression by using quantitative PCR in the
same set of mice. More importantly, we found similar data by
using two other sets of independent experiments, thereby
reinforcing the results observed with the microarray. Hepatic
insulin resistance has been widely associated with higher inﬂam-
matory tone.2 5 51 52 In this study, we found that several genes
involved in acute phase response, innate immunity and defence
were signiﬁcantly increased in mice lacking hepatocyte MyD88,
and this was observed under both normal diet and HFD condi-
tions. Surprisingly, numerous cytochrome P450 implicated in
the metabolism of long-chain fatty acids were downregulated,
with the exception of cytochromes involved in the biosynthesis
of bile acids (see ﬁgure 4 and online supplementary data). These
genes are involved in the synthesis of bioactive lipids that
belong to the arachidonic and linoleic acid metabolism, which
are EETs, HETEs and DHETs. These lipids have been associated
with both glucose metabolism and lipid metabolism. They have
also been shown to reduce hepatic steatosis and inﬂamma-
tion27 28 30 53 and were proposed as insulin sensitisers.29 31
Therefore, our data demonstrate a putative novel molecular link
between the innate immune system and synthesis of bioactive
lipids that contributes to regulate inﬂammation, glucose and
lipid metabolism.
TFactS analysis revealed a strong and signiﬁcant inhibition of
PPAR-α and LXRs in mice lacking hepatocyte MyD88 gene.
This observation is in line with the role of PPAR-α in controlling
various pathways of fatty acid synthesis, oxidation and bile acid
production. Interestingly, EETs, which are potentially decreased
in LKO mice, are known PPAR-α agonists.30 53 The increased
inﬂammation, hepatic steatosis and altered insulin sensitivity
observed in our model are in accordance with the inhibition of
PPAR-α and the observed phenotype. The potential downregu-
lation of LXR may also contribute to the modulation of immun-
ity, bile acids, glucose and lipid metabolism. In accordance with
the transcriptional analyses, we found that hepatocyte Myd88
deletion profoundly changes several bile acids levels. Among
these, two well-described bile acids controlling FXR activity
were modiﬁed, that is, CA and TbMCA. The FXR agonist CA
was decreased, whereas the FXR antagonist TbMCA was
increased in LKO and HFD-fed mice. This important ﬁnding
suggests that FXR activity is decreased in LKO mice and there-
fore validates the link with the phenotype observed on glucose,
lipid metabolism and inﬂammation (ﬁgure 5F, I, J).38 54 Among
the different bile acids, we found that primary bile acids were
mostly affected by the genetic deletion (CA and TbMCA),
whereas speciﬁc secondary bile acids such as deoxycholic acid
and lithocholic acid were increased by the dietary intervention
in the portal vein blood and in the caecal content, thereby
reﬂecting a putative implication of gut microbes. Our data
pointed towards an impaired FXR signalling in the liver (ﬁgure
5J) since we found an apparent decrease in abundance of a
major FXR agonist and a signiﬁcant increase of a FXR antagon-
ist, CA and TbMCA, respectively. Haeusler et al55 noted that a
relative deﬁciency of CA in mice contributes to a diabetic lipid
phenotype through impaired FXR signalling.
Importantly, we have been able to translate some of our data
observed in mice into human-relevant observations. In addition
to the different pathways depicted in online supplementary
ﬁgure S7 and table S7A, B, we found more speciﬁcally that
markers were discriminant between NASH versus non-NASH
patients. Cyp4z1, Cyp1b1, Cyp4a22 and Cyp2c19 were signiﬁ-
cantly decreased in patients with NASH. All these CYP450 are
involved in the synthesis of bioactive lipids that belong to the
EETs, HETEs and DHETs family.56–58 Thus, our human results
suggest that increased inﬂammatory markers (eg, Saa1, Saa2,
Cxcl1) characterising patients with NASH are independent of
the obesity status and are also associated with a putative defect
in the production of anti-inﬂammatory lipids. Strikingly, Saa1/2
and Cxcl1 are also markers that are highly expressed in LKO
mice and in HFD-fed mice.
However, whether a speciﬁc MyD88-dependent mechanism is
involved in the phenotype observed in humans warrants further
investigation. Nevertheless, data from the literature have shown
that TLR5 polymorphism protects from obesity but predisposes
to diabetes.59 In addition, TLR4 and IRF3 expression (MyD88
pathway) appear to be upregulated in the liver of patients suffer-
ing from NASH versus NAFLD, which is associated with
increased lipopolysaccharides (LPS) and fatty acid levels.60
In accordance with the bile acid proﬁle, we found that speciﬁc
bacterial genera were different between LKO and WT mice
during normal chow diet. Sutterella and Allobaculum were
decreased in LKO-CT mice and HFD-fed mice. It is worth
noting that Allobaculum is abundant and represents around
20% of the taxa found in CT mice. More importantly, most of
the previous studies have demonstrated that HFD feeding
reduces the presence of these taxa, whereas dietary interven-
tions that improve host metabolism (ie, insulin sensitivity,
inﬂammation) such as prebiotics or berberine, increase the
abundance of Sutterella and Allobaculum.14 45 61 62 Le Roy
et al have also shown that Allobaculum was higher in mice that
resist to HFD-induced metabolic disorders.63 Conversely,
the abundance of two other genera (Ruminococcus and
Oscillospira) was doubled in hepatocyte MyD88 deleted mice,
and even more increased upon HFD feeding. Interestingly, pre-
biotic treatment that improves host metabolism upon HFD
feeding decreases both Ruminococcus and Oscillospira in
diet-induced obese mice.61 The other major modiﬁcations of
the gut microbiota were mainly due to the dietary intervention.
In addition, consistent with our previous studies,61 64 we found
that altered metabolism and liver function observed during
HFD feeding were associated with a reduced expression of
Reg3g in both the jejunum and the ileum. However, other
markers of gut barrier function were only mildly affected
(Supplementary ﬁgure 3B, D).
Metabolomic analysis of both blood and liver compartment
shows that LKO mice segregate from WT-CT mice, both by che-
mometrics and by the amount of the metabolites. However, the
LKO mice exhibited major metabolomic changes under CT
treatment and very small differences under HFD treatment.
Most of the changes induced by LKO in CT mice were very
similar to those induced by an HFD treatment. Interestingly,
among the metabolites, several discriminant markers have been
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previously associated with diabetes and hepatic steatosis.
Long-chain fatty acids, branched chain amino acids (leucine, iso-
leucine and valine), markers of oxidation and reduction
(taurine, carnosine and total glutathione) were discriminant
between groups. Previous data have shown an association
between branched amino acids proﬁle, but also several other
metabolites, and the onset of insulin resistance and type 2 dia-
betes.65 66 Our results show that LKO under CT induces
changes in many metabolites related to branched chain amino
acid synthesis and metabolism (oxovalerates and aminobuty-
rates). Among them, NAC2, which recently have been reported
as markers of inﬂammation and have been related to type 2 dia-
betes and cardiovascular disease,67 are affected by both the LKO
and the HFD treatment. Choline, TMA and TMAO,68 which
also were discriminant between groups, associate with diabetes,
hepatic steatosis and furthermore cardiovascular disease.
Although the connection among all these elements is extremely
complex, our data suggest a new role of MyD88 in the develop-
ment of glucose intolerance and hepatic steatosis.
In conclusion, our study identiﬁes novel mechanisms linking
hepatic innate immunity and metabolism. We show, both in
mice and humans, that the expression of different cytochromes
involved in bile acid and bioactive lipid synthesis may serve as a
marker of susceptibility to develop metabolic disorders asso-
ciated with obesity including type 2 diabetes and NASH.
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